Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.51 |
| ▸ | GRK2 | P25098 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748823 | 1.00 | DGAT1 (0.51) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL594720 | 1.00 | DGAT1 (0.51) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL1748822 | 1.00 | DGAT1 (0.51) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL180513 | 1.00 | DGAT1 (0.51) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL195485 | 1.00 | DGAT1 (0.51) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL596331 | 0.96 | DGAT1 (0.55) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL596330 | 0.96 | DGAT1 (0.55) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL1748197 | 0.96 | DGAT1 (0.55) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL596332 | 0.96 | DGAT1 (0.55) | DGAT1GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL1748184 | 0.93 | DGAT1 (0.47) | DGAT1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024523-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (SE) | 2024-07-02 | — | — | US | disclosed |
| US-20230219967-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2023-07-13 | — | — | US | disclosed |
| US-11691978-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (SE) | 2023-07-04 | — | — | US | disclosed |
| US-20210355127-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2021-11-18 | — | — | US | disclosed |
| EP-3670499-B1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2021-09-29 | — | — | EP | disclosed |
| US-11001589-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (SE) | 2021-05-11 | — | — | US | disclosed |
| EP-3670499-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | Astrazeneca AB (SE) | 2020-06-24 | — | — | EP | disclosed |
| US-20200157113-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2020-05-21 | — | — | US | disclosed |
| EP-3292105-B1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2019-10-02 | — | — | EP | disclosed |
| US-20190084991-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2019-03-21 | — | — | US | disclosed |
| US-10183947-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (SE) | 2019-01-22 | — | — | US | disclosed |
| US-20180237439-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2018-08-23 | — | — | US | disclosed |
| EP-3292105-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | AstraZeneca AB (SE) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016177703-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2016-11-10 | — | — | WO | disclosed |
| EP-2155687-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| EP-1633722-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004100881-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157113-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
| US-20210355127-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
| US-10183947-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
| US-11691978-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
| US-20230219967-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
| US-20190084991-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
| US-12024523-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
| US-11001589-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
| US-20180237439-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LIPG, ALOX15 | DGAT1 792/4885GRK2 1538/4885CASP6 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.